A Phase 4 interventional study of hylenex-facilitated subcutaneous Lactated Ringer's infusion in Dehydration, sponsored by Baxter Healthcare Corporation. Completed at 2 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-26.
Sponsored by Baxter Healthcare Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Dehydration with a site in United States — 7 open to participants now, 8 under way, none of them phase 3. Dehydration · United States.
Among the 87 studies in Dehydration with a site in United States, this one is the 13th largest by enrollment of the 74 interventional ones that give a count, is one of 2 that started in 2008, is one of 6 in phase 4, and was the 8th registered.
201 studies on the registry are indexed under Dehydration; 28 are open to participants now.
Browse Dehydration studies →7 of the 87 studies in Dehydration with a site in United States are open now. Recruiting first, the newest first:
State University of New York at Buffalo · Sites in United States
Ages 18–60
PepsiCo Global R&D · Sites in United States
Ages 18–60 · Women only · Healthy volunteers
Duquesne University · Sites in United States
Ages 60+ · Healthy volunteers
University of Iowa · Sites in United States
Ages 18–60
Arizona State University · Sites in United States
Ages 20–65 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Dehydration studies recruiting now, 7 (47%) set no upper age limit and 7 (47%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 3 · Phase 4 6
First in 2005; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 44 across 145 interventional studies indexed under Dehydration.
Median enrollment 30 across the 74 interventional studies, 82 across the 13 observational. Of the 73 that completed or were terminated, 17 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 87 have an industry lead sponsor. The 10 most frequent:
Baxter Healthcare Corporation is the lead sponsor of 80 studies on the registry; 1 is open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.
Baxter Healthcare Corporation has 5 studies filed under Dehydration — fewer than ten, so there is no comparison to draw.
5 of the studies in Dehydration with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07653620PepsiCo Global R&DHydration & Female Life Stages | 2026-11 |
| NCT06847256University of IowaGenetic Risk Factor for Heat Stroke | 2026-12 |
| NCT07641361State University of New York at BuffaloHydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy | 2027-02-01 |
| NCT07658820Arizona State UniversityThe Role of Carbohydrate Blends and Electrolytes on Physical and Mental Performance During Cycling in the Heat | 2027-03-30 |
| NCT02253238M.D. Anderson Cancer CenterSensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients | 2027-04-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 87 studies in Dehydration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose is to evaluate the ease of use and technical challenges encountered during subcutaneous infusion of Lactated Ringer's (LR) solution, preceded by recombinant human hyaluronidase (hylenex), utilizing commonly used angiocatheter gauges and button delivery systems. The safety and tolerability of hylenex-augmented SC infusion of LR through these delivery systems is also being evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, Teflon angiocatheter secured with Tegaderm
Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion
subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, Teflon angiocatheter secured with a tape double chevron
Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion
subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, polyurethane angiocatheter secured with Tegaderm
Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion
subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, polyurethane angiocatheter secured with a tape double chevron
Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion
subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, Teflon angiocatheter secured with Tegaderm
Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion
subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, Teflon angiocatheter secured with a tape double chevron
Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion
subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, polyurethane angiocatheter secured with Tegaderm
Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion
subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, polyurethane angiocatheter secured with a tape double chevron
Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion
subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a button-type subcutaneous delivery system (with a 27-gauge, 9 mm long metal needle)
Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion
single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution
Also known as: hylenex, rHuPH20, LR, LR solution
Technical Challenges
Protocol-specified challenges encountered during subcutaneous (SC) hylenex administration and/or SC infusion of Lactated Ringer's solution, including SC catheter kinking, catheter/button dislodgement, catheter/button pull-out, infusion pump alarm, other pump failure, healthcare provider intervention to secure/maintain SC infusion eg, re-taping, catheter/button manipulation, etc, and any other type of technical challenge encountered
Time frame: throughout subcutaneous hylenex and fluid administration period (continuous)
Attempts Needed to Successfully Place Subcutaneous Catheter/Button
Time frame: from start of first attempt until completion of catheter/button placement
Time Needed to Successfully Place Subcutaneous Catheter/Button
Time frame: from start of first attempt until completion of catheter/button placement
Time Required to Infuse 1000 mL Fluid
Time frame: from start of Lactated Ringer's (LR) infusion until 1000 mL LR infused
| Milestone | Tegaderm-secured 24 ga Teflon Catheter | Tape-secured 24 ga Teflon Catheter | Tegaderm-secured 24 ga Polyurethane Catheter | Tape-secured 24 ga Polyurethane Catheter | Tegaderm-secured 20 ga Teflon Catheter | Tape-secured 20 ga Teflon Catheter | Tegaderm-secured 20 ga Polyurethane Catheter | Tape-secured 20 ga Polyurethane Catheter | SC Button With 27 ga X 9 mm Needle |
|---|---|---|---|---|---|---|---|---|---|
| Started | 10 | 11 | 11 | 10 | 12 | 12 | 12 | 11 | 11 |
| Completed | 10 | 11 | 11 | 10 | 12 | 11 | 12 | 11 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Protocol-specified challenges encountered during subcutaneous (SC) hylenex administration and/or SC infusion of Lactated Ringer's solution, including SC catheter kinking, catheter/button dislodgement, catheter/button pull-out, infusion pump alarm, other pump failure, healthcare provider intervention to secure/maintain SC infusion eg, re-taping, catheter/button manipulation, etc, and any other type of technical challenge encountered
| participants | Tegaderm-secured 24 ga Teflon Catheter | Tape-secured 24 ga Teflon Catheter | Tegaderm-secured 24 ga Polyurethane Catheter | Tape-secured 24 ga Polyurethane Catheter | Tegaderm-secured 20 ga Teflon Catheter | Tape-secured 20 ga Teflon Catheter | Tegaderm-secured 20 ga Polyurethane Catheter | Tape-secured 20 ga Polyurethane Catheter | SC Button With 27 ga X 9 mm Needle |
|---|---|---|---|---|---|---|---|---|---|
| Subjects with at Least One Technical Challenge | 2 | 3 | 2 | 2 | 2 | 2 | 3 | 2 | 3 |
| Subjects with No Technical Challenges | 8 | 8 | 9 | 8 | 10 | 10 | 9 | 9 | 8 |
| Subjects with 1 TEchnical Challenge | 2 | 3 | 2 | 1 | 2 | 2 | 3 | 0 | 3 |
| Subjects with 2 Technical Challenges | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Subjects with 3 Technical Challenges | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Subjects with Catheter Kinking | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 2 | 0 |
| Subjects with Catheter Dislodgement | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Subjects with Catheter Pulled Out | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Subjects with Infusion Pump Alarm | 2 | 2 | 2 | 1 | 2 | 2 | 3 | 1 | 3 |
| Subjects with Infusion Pump Failure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| participants | Tegaderm-secured 24 ga Teflon Catheter | Tape-secured 24 ga Teflon Catheter | Tegaderm-secured 24 ga Polyurethane Catheter | Tape-secured 24 ga Polyurethane Catheter | Tegaderm-secured 20 ga Teflon Catheter | Tape-secured 20 ga Teflon Catheter | Tegaderm-secured 20 ga Polyurethane Catheter | Tape-secured 20 ga Polyurethane Catheter | SC Button With 27 ga X 9 mm Needle |
|---|---|---|---|---|---|---|---|---|---|
| 1 Attempt | 10 | 11 | 10 | 10 | 12 | 11 | 12 | 11 | 11 |
| 2 Attempts | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| seconds | Tegaderm-secured 24 ga Teflon Catheter | Tape-secured 24 ga Teflon Catheter | Tegaderm-secured 24 ga Polyurethane Catheter | Tape-secured 24 ga Polyurethane Catheter | Tegaderm-secured 20 ga Teflon Catheter | Tape-secured 20 ga Teflon Catheter | Tegaderm-secured 20 ga Polyurethane Catheter | Tape-secured 20 ga Polyurethane Catheter | SC Button With 27 ga X 9 mm Needle |
|---|---|---|---|---|---|---|---|---|---|
| Time Needed to Successfully Place Subcutaneous Catheter/Button | 23 (1 to 39) | 43 (2 to 84) | 30 (2 to 63) | 34 (10 to 96) | 30 (2 to 58) | 49 (2 to 133) | 31 (1 to 90) | 15 (1 to 96) | 9 (1 to 47) |
| hours | Tegaderm-secured 24 ga Teflon Catheter | Tape-secured 24 ga Teflon Catheter | Tegaderm-secured 24 ga Polyurethane Catheter | Tape-secured 24 ga Polyurethane Catheter | Tegaderm-secured 20 ga Teflon Catheter | Tape-secured 20 ga Teflon Catheter | Tegaderm-secured 20 ga Polyurethane Catheter | Tape-secured 20 ga Polyurethane Catheter | SC Button With 27 ga X 9 mm Needle |
|---|---|---|---|---|---|---|---|---|---|
| Time Required to Infuse 1000 mL Fluid | 6.82 ± 0.058 | 6.78 ± 0.098 | 6.81 ± 0.013 | 6.80 ± 0.114 | 6.78 ± 0.071 | 6.80 ± 0.013 | 6.81 ± 0.078 | 6.79 ± 0.108 | 6.82 ± 0.078 |
Collected over 6 d post-treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tegaderm-secured 24 ga Teflon Catheter | — | 0/10 (0%) | 6/10 (60%) |
| Tape-secured 24 ga Teflon Catheter | — | 0/11 (0%) | 5/11 (45.5%) |
| Tegaderm-secured 24 ga Polyurethane Catheter | — | 0/11 (0%) | 9/11 (81.8%) |
| Tape-secured 24 ga Polyurethane Catheter | — | 0/10 (0%) | 7/10 (70%) |
| Tegaderm-secured 20 ga Teflon Catheter | — | 1/12 (8.3%) | 9/12 (75%) |
| Tape-secured 20 ga Teflon Catheter | — | 0/12 (0%) | 10/12 (83.3%) |
| Tegaderm-secured 20 ga Polyurethane Catheter | — | 0/12 (0%) | 10/12 (83.3%) |
| Tape-secured 20 ga Polyurethane Catheter | — | 0/11 (0%) | 10/11 (90.9%) |
| SC Button With 27 ga X 9 mm Needle | — | 0/11 (0%) | 8/11 (72.7%) |
| Event | Tegaderm-secured 24 ga Teflon Catheter | Tape-secured 24 ga Teflon Catheter | Tegaderm-secured 24 ga Polyurethane Catheter | Tape-secured 24 ga Polyurethane Catheter | Tegaderm-secured 20 ga Teflon Catheter | Tape-secured 20 ga Teflon Catheter | Tegaderm-secured 20 ga Polyurethane Catheter | Tape-secured 20 ga Polyurethane Catheter | SC Button With 27 ga X 9 mm Needle |
|---|---|---|---|---|---|---|---|---|---|
| calculus uretericRenal and urinary disorders | 0/10 | 0/11 | 0/11 | 0/10 | 1/12 | 0/12 | 0/12 | 0/11 | 0/11 |
| Event | Tegaderm-secured 24 ga Teflon Catheter | Tape-secured 24 ga Teflon Catheter | Tegaderm-secured 24 ga Polyurethane Catheter | Tape-secured 24 ga Polyurethane Catheter | Tegaderm-secured 20 ga Teflon Catheter | Tape-secured 20 ga Teflon Catheter | Tegaderm-secured 20 ga Polyurethane Catheter | Tape-secured 20 ga Polyurethane Catheter | SC Button With 27 ga X 9 mm Needle |
|---|---|---|---|---|---|---|---|---|---|
| Infusion site painGeneral disorders | 2/10 | 4/11 | 4/11 | 3/10 | 6/12 | 9/12 | 8/12 | 8/11 | 3/11 |
| Infusion site erythemaGeneral disorders | 3/10 | 2/11 | 4/11 | 2/10 | 2/12 | 3/12 | 2/12 | 4/11 | 3/11 |
| Infusion site swellingGeneral disorders | 0/10 | 1/11 | 1/11 | 2/10 | 3/12 | 4/12 | 3/12 | 0/11 | 1/11 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/10 | 1/11 | 0/11 | 3/10 | 1/12 | 2/12 | 0/12 | 0/11 | 2/11 |
| HeadacheNervous system disorders | 1/10 | 0/11 | 1/11 | 0/10 | 1/12 | 1/12 | 0/12 | 2/11 | 0/11 |
| Age, Categorical(Participants) | Tegaderm-secured 24 ga Teflon Catheter | Tape-secured 24 ga Teflon Catheter | Tegaderm-secured 24 ga Polyurethane Catheter | Tape-secured 24 ga Polyurethane Catheter | Tegaderm-secured 20 ga Teflon Catheter | Tape-secured 20 ga Teflon Catheter | Tegaderm-secured 20 ga Polyurethane Catheter | Tape-secured 20 ga Polyurethane Catheter | SC Button With 27 ga X 9 mm Needle | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 11 | 11 | 10 | 12 | 12 | 12 | 11 | 11 | 100 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age Continuous(years) | Tegaderm-secured 24 ga Teflon Catheter | Tape-secured 24 ga Teflon Catheter | Tegaderm-secured 24 ga Polyurethane Catheter | Tape-secured 24 ga Polyurethane Catheter | Tegaderm-secured 20 ga Teflon Catheter | Tape-secured 20 ga Teflon Catheter | Tegaderm-secured 20 ga Polyurethane Catheter | Tape-secured 20 ga Polyurethane Catheter | SC Button With 27 ga X 9 mm Needle | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 34.6 ± 9.39 | 36.0 ± 10.6 | 33.8 ± 10.4 | 35.3 ± 10.9 | 34.0 ± 12.5 | 34.3 ± 10.3 | 33.6 ± 10.7 | 32.4 ± 12.7 | 36.6 ± 12.3 | 34.5 ± 10.8 |
| Sex: Female, Male(Participants) | Tegaderm-secured 24 ga Teflon Catheter | Tape-secured 24 ga Teflon Catheter | Tegaderm-secured 24 ga Polyurethane Catheter | Tape-secured 24 ga Polyurethane Catheter | Tegaderm-secured 20 ga Teflon Catheter | Tape-secured 20 ga Teflon Catheter | Tegaderm-secured 20 ga Polyurethane Catheter | Tape-secured 20 ga Polyurethane Catheter | SC Button With 27 ga X 9 mm Needle | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 1 | 8 | 3 | 3 | 6 | 5 | 4 | 5 | 38 |
| Male | 7 | 10 | 3 | 7 | 9 | 6 | 7 | 7 | 6 | 62 |
| Region of Enrollment(participants) | Tegaderm-secured 24 ga Teflon Catheter | Tape-secured 24 ga Teflon Catheter | Tegaderm-secured 24 ga Polyurethane Catheter | Tape-secured 24 ga Polyurethane Catheter | Tegaderm-secured 20 ga Teflon Catheter | Tape-secured 20 ga Teflon Catheter | Tegaderm-secured 20 ga Polyurethane Catheter | Tape-secured 20 ga Polyurethane Catheter | SC Button With 27 ga X 9 mm Needle | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | 10 | 11 | 11 | 10 | 12 | 12 | 12 | 11 | 11 | 100 |
The record gives a start of Dec 2008, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyaluronidase (human recombinant)
Baxter Healthcare Corporation →